뒤로
Cynata Therapeutics Limited(CYYNF) 가격
CYYNF 주가 차트
CYYNF 수입
Cynata Therapeutics Limited
$0.22
0%
$0
종가: Feb 06, 16:00:00 GMT-5
$0.22
0%
$0
애프터마켓: Feb 06, 20:00:00 GMT-5
Earnings FAQ
CYYNF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Cynata Therapeutics Limited CYYNF의 지난 분기 매출 실적은 어땠나요?
Cynata Therapeutics Limited의 매출 추정치는 얼마인가요?
Cynata Therapeutics Limited의 수익 품질 점수는 얼마인가요?
Cynata Therapeutics Limited는 언제 수익을 보고하나요?
Cynata Therapeutics Limited의 예상 수익은 얼마인가요?
Cynata Therapeutics Limited은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.22
시가
$0.11
일일 범위
$0.11 - $0.22
52주 범위
$0.08 - $0.22
거래량
220
평균 거래량
57
EPS(TTM)
-0.03
배당수익률
--
시가총액
$52.2M
CYNATA THERAPEUTICS LTD란 무엇인가요?
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.